At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
CC-122 +1 moredrug
Likely dose
CC-122 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Biomarker Trial of Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Feb 8, 2019·Updated Oct 5, 2022
In Brief
A Phase 2 clinical trial evaluating CC-122 and Nivolumab for Melanoma. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This study is to find out if the combination of CC-122 (an investigational agent) and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are responsible for maintaining the body's immune response).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Celgene Corporation
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMay 2019
Primary CompletionJun 2021
Study CompletionAug 2021
TodayJul 2026
First PostedFeb 8, 2019
Enrollment StartMay 14, 2019
Primary CompletionJun 29, 2021
Study CompletionAug 4, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.4 years ago
Interventions
CC-122drug
Oral CC-122 at 2 mg daily, 5 days out of 7
Nivolumabdrug
240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle